Author(s):
Sangramsing Dipaksing Deshmukh, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani, Sunil Pandit Pawar
Email(s):
sangramsingdeshmukh@gmail.com
DOI:
10.52711/2231-5675.2026.00043 
Address:
Sangramsing Dipaksing Deshmukh, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani, Sunil Pandit Pawar
Department of Pharmaceutical Quality Assurance, P.S.G.V.P. Mandals College of Pharmacy, Shahada. Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon 425004. Maharashtra India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Baricitinib is an orally administered, selective Janus kinase (JAK1 and JAK2) inhibitor widely prescribed for the management of rheumatoid arthritis and other inflammatory disorders. Owing to its expanding clinical applications and therapeutic importance, the development of robust, precise, and stability indicating analytical methods is essential to ensure its quality, safety, and efficacy in pharmaceutical formulations. This review comprehensively summarises the analytical approaches reported for the estimation of Baricitinib in bulk drug and dosage forms, with particular emphasis on reverse-phase high-performance liquid chromatography (RP-HPLC). The discussed RP-HPLC methods demonstrate excellent performance characteristics in accordance with ICH validation guidelines, including accuracy, precision, linearity, specificity, range, limit of detection (LOD), limit of quantification (LOQ), robustness, and ruggedness. In addition to chromatographic techniques, complementary methods such as UV–Visible spectroscopy, UHPLC, HPTLC, and LC-MS/MS are also highlighted. Overall, validated analytical methodologies play a critical role in pharmaceutical quality control, regulatory compliance, and stability assessment, ensuring consistent therapeutic performance of Baricitinib-containing formulations.
Cite this article:
Sangramsing Dipaksing Deshmukh, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani, Sunil Pandit Pawar. Analytical Method Development and Validation of Baricitinib: A Comprehensive Review of RP-HPLC and Spectroscopic Techniques. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):279-4. doi: 10.52711/2231-5675.2026.00043
Cite(Electronic):
Sangramsing Dipaksing Deshmukh, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani, Sunil Pandit Pawar. Analytical Method Development and Validation of Baricitinib: A Comprehensive Review of RP-HPLC and Spectroscopic Techniques. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):279-4. doi: 10.52711/2231-5675.2026.00043 Available on: https://www.ajpaonline.com/AbstractView.aspx?PID=2026-16-4-5
REFERENCES:
1. O’Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., and Laurence, A. (2015). Janus kinase inhibitors in autoimmune diseases (pp. ii111–ii115). Annals of the Rheumatic Diseases, 74(Suppl 2).
2. International Council for Harmonisation (ICH). (2005). ICH Q2(R1): Validation of Analytical Procedures — Text and Methodology. Geneva.
3. O’Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., and Laurence, A. Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases. 2015; 74(Suppl 2): ii111–ii115.
4. Eli Lilly and Company. (2018). Olumiant (Baricitinib) prescribing information. Indianapolis, USA.
5. National Centre for Biotechnology Information. (2024). PubChem Compound Summary: Baricitinib. Available from the PubChem database.
6. Shi, J. G., Chen, X., Lee, F., Emm, T., Scherle, P. A., Lo, Y., et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib in healthy subjects. Clinical Pharmacology in Drug Development. 2014; 3(5): 367–374.
7. Choy, E. H., Miceli-Richard, C., González-Gay, M. A., Sinigaglia, L., Schlichting, D. E., Meszaros, G., et al. Pharmacokinetic profile of baricitinib in patients with rheumatoid arthritis. Rheumatology and Therapy. 2018; 5(2): 461–472.
8. Taylor, P. C., Keystone, E. C., van der Heijde, D., Weinblatt, M. E., Del Carmen Morales, L., Reyes Gonzaga, J., et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine. 2017; 376(7): 652–662.
9. U.S. Food and Drug Administration. (2018). Clinical Pharmacology Review: Baricitinib (Olumiant).
10. National Centre for Biotechnology Information. PubChem Compound Summary: Baricitinib.
11. Zhang, X., Peck, R., Van Brummelen, P., and Gupta, P. Population pharmacokinetics of baricitinib in patients with rheumatoid arthritis. Clinical Pharmacokinetics. 2017; 56(12): 1523–1534.
12. Fridman, J. S., Scherle, P. A., Collins, R., Burn, T., Li, Y., Li, J., et al. Selective inhibition of JAK1 and JAK2 by baricitinib and its impact on cytokine signalling. Journal of Immunology. 2010; 184(9): 5298–5307
13. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2005). ICH Q2(R1): Validation of Analytical Procedures — Text and Methodology. Geneva.
14. Ramole Rina, Mohini Baile, Ashish Jain.
15. Hokanson GC.A life cycle approach to the validation of analytical methods during pharmaceutical product development, Part I: The initial validation process. Pharm.Tech. 1994; 118–30.
16. Sahoo NK, Sahu M, Veerachamy A, Lalitha BV, Moharana AK, Sahoo CK. Quantification and validation of simvastatin and ezetimibe in bulk drugs and combined dosage form by reverse phase liquid chromatographic method (RPLC). Pharm.Methods 2015; 6(2): 115–9.
17. Sahoo NK, Sahu M, Alagarsamy V, Srividya B, Sahoo CK. Current status of two-dimensional gel validation of assay indicating method development of imatinib in bulk and its capsule dosage form by liquid chromatography. Ann. Chromatogr Sep. Tech.2015; 1(2): 1010.
18. Moharana AK, Banerjee M, Sahoo CK, Sahoo NK. Development and validation of an RP-HPLC method for mesalamine. Asian J. of Pharmaceutical and Clinical Research 2011; 4(Suppl.2):71–73.
19. Reddy V.P, Rajan T.V.S, Kumar A. N, A Review on Analytical Method Validation. Int J Rev Life Sci. 1: 141–144.
20. Chinmaya K. S, Muvvala S., Nalini K. S., Validation of Analytical Methods: A Review, International Journal of Chromatography and Separation Techniques. 2018;1
21. Nagdev, S. A., Bhurat, M. R., Usman, M. R. M., Gupta, K. R., and Gandagule, U. B. (2019, January). Pharmaceutical Quality Assurance (pp. 3–4).
22. Venkateswarlu, K., Devanna, N., Haritha, A., and Farihath, M. S. (2013). UV-Visible Spectroscopy. PharmaTutor Articles.
23. Vidushi, Y., and Meenakshi, B. A review of HPLC method development and validation. Life Science Informatics Publications, RJLBPCS. 2017; 2(6).
24. UKEssays. (2018, November). Review of Ultra High-Performance Liquid Chromatography and High-Performance Liquid Chromatography.
25. Gupta, S., Verma, P., Mishra, A. P., Omar, N., and Mathur, R. A review of novel analytical method development and validation by the RP-HPLC method. Indian Journal of Forensic Medicine and Toxicology. 2021; 15(4).
26. Ramole, R., Baile, M., and Jain, A. (). A review: Analytical method development and validation. Systematic Review in Pharmacy. 2021; 12(8).
27. Eleni Kakouri1 Identification and structural characterisation of potential degradation products of baricitinib using liquid chromatography combined with quadrupole time-of-flight mass spectrometry. Acta Chromatographica. 2024 Apr; 37(1): 6–108.
28. Illendula S, Prasad PS. Analytical method development and validation of RP-HPLC for the quantitative determination of baricitinib in pure substances and marketed formulations. International Journal of Pharmacy and Biological Sciences. 2022 Jul; 12(3): 108–14.
29. S. Mohan, N Srinivasarao. Development and validation of a stability-indicating related substances method of baricitinib by RP-HPLC and its degradation. International Journal of Management and Humanities. 2019 Mar; 4(2): 4–9.
30. Kiran Kumar Gannamani Development and validation of stability-indicating RP-HPLC method for the determination of baricitinib and its related drug substances. Rasayan Journal of Chemistry. 2023 Aug; 16(3): 1163–73.
31. Khagga Bhavya Sri1 Development and validation of a stability-indicating UV spectroscopic method for baricitinib in bulk and formulation. Pharmaceutical Sciences and Drug Design. 2022 Aug; 2: 8–13.
32. J´ er´ emie Tachet Development and validation of a multiplex HPLC-MS/MS assay for monitoring JAK inhibitors in patient plasma. Journal of Chromatography B. 2023 Oct; 1230: 1–9.